Creo Medical Group’s ‘Speedboat’ surgical technology piloted in Wales
Published: 04:44 06 Feb 2025 EST
Creo Medical Group PLC (AIM:CREO) has announced that Aneurin Bevan University Health Board (ABUHB) has become the first in Wales to implement its ‘Speedboat’ technology in a six-month pilot program.
Speedboat – or to give it its full title Speedboat Submucosal Dissection or SSD – is described as “a minimally invasive treatment to remove colorectal polyps, can allow clinicians to treat patients in a single procedure and avoid major surgery.
Since the pilot's launch, just before Christmas, three patients with ‘complex’ type polyps have been successfully treated without complications and were discharged on the same day, Creo Medical noted.
“As a Welsh company, it is exciting that the Aneurin Bevan team are the first in Wales to use our Speedboat for the benefit of its colon cancer patients; the SSD pilot in could enhance patient outcomes, reduce surgical waiting lists, and facilitate the wider adoption of this technique across other Health Boards in Wales,” Creo chief executive Craig Gulliford said.
Rob Holcombe, finance director for ABUHB, meanwhile, commented: “The early success of this pilot highlights the Board's commitment to delivering solutions that enhance patient care, reduce pressure on surgical services and demonstrate ABUHB's approach to adopting medical innovation through 'value-based health care' outcome evaluation."
The project’s clinical lead, Dr Alka Joshi added: "This pilot is a significant step forward for our patients.
“By utilising the Speedboat device, we can offer a more efficient, less invasive alternative to traditional surgical methods, improving outcomes and reducing waiting times."
